Document is current
Any future updates will be listed below
-
Authors
Willemse, Ilse H. J.
Mellone, Sabato
Tacconi, Carlo
Ilg, Winfried
Schüle, Rebecca
Synofzik, Matthis
Nonnekes, Jorik H.
van de Warrenburg, Bart P. C.
-
Funding
Funding for this research was provided by:
ZonMw (463002002)
the Deutsche Forschungsgemeinschaft (441409627)
- License Information
-
More Information
Article History
Accepted: 9 March 2025
First Online: 24 March 2025
Declarations
:
: We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. This study was approved by the medical ethical committee of Arnhem-Nijmegen (CMO-2020-6245). All participants provided written informed consent before enrollment.
: Ilse H.J. Willemse was supported by ZonMw (The Netherlands Organisation for Health Research and Development; grant number 463002002). Jorik H. Nonnekes has received research support from ZonMW, Parkinson Foundation, Michael J Fox Foundation and Gossweiler Foundation. Bart P.C. van de Warrenburg has received research support from ZonMw, Dutch Scientific Organization, Hersenstichting, Radboudumc, and the Christina Foundation, and has received consultancy fees from Biogen, Biohaven Pharmaceuticals, Servier, and Vico Therapeutics. Matthis Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly, and Solaxa, all unrelated to the present manuscript. Rebecca Schüle received sponsoring and honoraria by Abbvie, Bial, Everpharma and Stada, all unrelated to the manuscript.
: SM and CT own a share in the spin-off company of the University of Bologna, mHealth Technologies s.r.l. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
